| Description |
1 online resource (278 p.) |
| Contents |
Intro -- Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology: From Basic Research to Advanced Study -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1 Overview of changes in the cardiovascular system -- 1 Introduction -- 2 Circulatory system -- 2.1 Pulmonary circulation -- 2.2 Systemic circulation -- 3 Blood vessels -- 3.1 Veins -- 3.2 Arteries -- 3.3 Capillaries -- 4 Heart valves -- 5 Physiology of heart -- 6 Cardiac cycle -- 7 Heart sounds -- 8 Heart rate -- 9 Blood |
|
10 Effects on the cardiovascular system due to various physical/environmental factors -- 10.1 Effects due to aging -- 10.2 Effects due to exercise -- 10.3 Effects due to anesthetics -- 11 Conclusion -- References -- Chapter 2 Cardiovascular disease in cancer survivors: Risk and management -- 1 Introduction -- 2 Section 1: Underlying risk factors: Genetic and environmental -- 2.1 Common risk factors -- 2.2 Genetic risk factors -- 2.3 Environmental risk factors -- 2.3.1 Inflammation in CVD and cancer -- 2.3.2 Air pollution -- 2.3.3 Tobacco use and smoking -- 2.3.4 Alcohol consumption |
|
2.3.5 Diet -- 2.3.6 Organic and inorganic chemicals -- 3 Section 2: Health behaviors: Overweight and obesity, hyperlipidemia, hypertension, insulin resistance, and metabolic ... -- 3.1 Metabolic syndrome -- 3.2 Overweight and obesity -- 3.3 Insulin resistance -- 3.4 Hyperlipidemia -- 3.5 Hypertension -- 4 Section 3: Management of risk factors -- 5 Conclusion -- References -- Chapter 3 Recent trends in cancer immunotherapy: Pathways and inhibitors -- 1 Introduction -- 2 CTLA-4 and PD-1 pathways -- 2.1 Immune therapy -- 3 PI3K/AKT/mTOR signaling pathways -- 3.1 Immune therapy |
|
4 Concluding remarks -- References -- Chapter 4 Stroke risk assessment and atrial fibrillation (AF) in cancer patients -- 1 Introduction -- 2 Association between cancer and atrial fibrillation (AF) -- 3 Management and treatment modalities of AF -- References -- Chapter 5 Biochemistry of biomarkers in cardiotoxicity induced in chemotherapeutic drugs -- 1 Introduction -- 2 Biomarker discovery pipeline -- 3 Prevalence of cancer and its management strategies -- 3.1 Radiation therapy -- 3.2 Chemotherapy -- 4 Cardiotoxicity due to anticancer therapy |
|
4.1 Effect of reactive oxygen species (ROS) -- 4.2 Thrombosis -- 4.3 Cardiac mitochondrial dysfunction -- 5 Biomarkers and its molecular aspects in cardiotoxicity -- 5.1 Cardiac troponins (cTn) -- 5.2 Natriuretic peptides (NPs) -- 5.3 Inflammatory biomarkers -- 5.4 Ischemic biomarkers -- 5.5 Biomarkers of endothelial dysfunction -- 6 Future challenges and concluding remarks -- Acknowledgment -- Funding -- Conflict of interest -- Availability of data and materials -- Authors' contribution -- Ethics approval -- Consent for publication -- References |
| Notes |
Description based upon print version of record |
|
Chapter 6 Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR |
| Form |
Electronic book
|
| Author |
Maurya, Pawan Kumar
|
| ISBN |
9780323904629 |
|
0323904629 |
|
